Gendicine is a recombinant human p53 adenovirus particle that has infectious activity. It is composed of the adenovirus vector and normal p53 tumor suppressor gene (wt-p53). When used in gene therapy of tumor, its function depends on the full expression of the gene p53 to produce P53 protein in the tumor cells.
    After injection, the expression level of the gene p53 increases gradually in tumor cells, and reaches the peak in 48-72 hrs, and then falls down to about 30% in 120 hrs.
The acting mechanism of radiotherapy is to induce chromosomal mutation in the radiated tumor cells, and thermotherapy to heat-denature the protein. To minimize the destructive effect of radiation and heat to the genes and proteins of adenovirus and p53, radiotherapy or thermotherapy, when in combination with Gendicine, is recommended to be applied 48-72 hrs after Gendicine injection.
    Combined with Gendicine, radiotherapy was ever used at the intensity of 40, 50, 60, and 70 Gy. Higher intensity show better efficacy than the lower ones.